IPSC
Century Therapeutics, Inc.·Healthcare
2.25
0.442%(−0.01)
Market ClosedLast Updated: — ET
52W L: $0.4352W H: $3.04
IPSC NEWS
defenseworld.net
Mar 5
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.80
Shares of Century Therapeutics, Inc. (NASDAQ: IPSC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy
globenewswire.com
Feb 25
Century Therapeutics to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March:
defenseworld.net
Feb 24
Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF)
Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current
globenewswire.com
Feb 16
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
seekingalpha.com
Feb 9
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived β-cell therapy, CNTY-813. IPSC's Allo-Evasion platform uniquely targets T-cell, NK-cell, and humoral immunity, potentially offering superior long-term engraftment and immune escape versus competitors like SANA, VRTX, and CRSP. With cash runway to Q1 2029 and a recent $135M PIPE from major biotech funds, IPSC is well-capitalized to advance its T1DM program toward IND submission in 2026 and initial clinical data in 2027.
zacks.com
Jan 22
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
